A year after its initial launch as QuintilesIMS, the pharma service provider has re-launched as IQVIA.
Its new name maintains parts of its original formation, with the ‘I’ representing IMS and the ‘Q’ taken from Quintiles.
However, the latter and newest part of the name – ‘via’ – is representative of “seeking to inspire and ignite real change via a new path forward”, explains Ari Bousbib, chief executive officer of IQVIA.
Bousbib added: “We launched as QuintilesIMS, then we built something transformational and that is how we became IQVIA.
“We aim to bring the potential of human data science to life to find better solutions for patients.”
The group has a slightly different offering from when it first became QuintilesIMS, which was due to a mega-merger of healthcare services provider Quintiles and information and technology group IMS, offering pharma clients an end-to-end clinical and commercial package.
Now, the newly-named group will provide solutions to healthcare companies through analytics, data science and human science, claiming expertise in research and development, real-world value and outcomes, commercialisation and technologies.